NasdaqGS:SYREBiotechs
How Does Spyre Therapeutics’ New CCO Shape SYRE’s Path From Pipeline To Commercial Strategy?
Spyre Therapeutics recently expanded its leadership team by appointing former Amgen executive Kate Tansey Chevlen as Chief Commercial Officer, adding nearly two decades of global biopharma commercial experience to guide its late-stage development and commercialization plans.
This hire, paired with the company’s 2026 roadmap of six planned proof-of-concept readouts across its SKYLINE and SKYWAY trials, highlights a coordinated push to convert scientific programs into potential market-ready...